AI-generated analysis. Always verify with the original filing.
Corvus Pharmaceuticals, Inc. entered into an Amended and Restated Open Market Sale Agreement SM on March 13, 2026. The agreement is filed as Exhibit 1.1.
Event Type
Disclosure
Mandatory
Variant
8-K
. Entry into a Material Definitive Agreement. On March 13, 2026, the Company entered into an Amended and Restated Open Market Sale Agreement SM (the “Amended Sa
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Amended and Restated Open Market Sale Agreement SM , dated March 13, 2026, by and b
Material Agreement